The antibacterial medicine market in Türkiye has seen significant fluctuations over the past decade. Starting with a value of 1.18 billion New Turkish Liras in 2013, growth was modest until 2018 when the market began a pronounced upward trend, especially notable from 2019 onwards. The most recent actual data from 2023 shows a value of 2.87 billion New Turkish Liras, indicating a robust growth trajectory.
Year-on-year variations reveal substantial volatility in the market. Sharp increases were observed in 2019 (38.15%) and 2021 (20.24%), contrasting periods of decline like in 2014 (-3.47%) and 2020 (-15.52%). Over the last two years, the market has experienced a more stable growth with rates of 6.36% in 2022 and 13.2% in 2023. The compound annual growth rate (CAGR) from 2018 to 2023 was 11.06%.
Looking ahead from 2024, the forecast indicates continued growth, although at a more moderate pace with a projected five-year CAGR of 4.68% and an overall growth rate of 25.69% by 2028. This suggests a steady yet less volatile market expansion.
Future trends to watch for include advancements in antibacterial drug formulations, regulatory changes, and the potential impact of healthcare policy reforms. Continued monitoring of global health trends and resistance patterns will also be crucial for market stakeholders.
